Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Celecoxib in Advanced mCRC
NCT05281276Phase 1Terminated
- Sponsor
- Taipei Medical University Shuang Ho Hospital
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tucidinostat in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Taipei Medical University Shuang Ho Hospital. Primary endpoints: Maximum Feasible Dose at 28 days, Area Under the Curve (0-t) and 1 more. Started Sep 2022; status: terminated.
02
Drugs
tucidinostat
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05281276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281276.